Glioma
Conditions
Interventions
Group1:Standard treatment only.
Group2 (Age 18):Standard treatment + Atorvastatin.
Sponsors
The Third Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
1 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Pathologic diagnosis: histologically or cytologically confirmed intracranial primary glioma (WHO grade 1-4), including newly diagnosed or recurrent glioma. 2. Age: Unlimited. 3. Expected survival: more than 3 months. 4. Treatment history: no treatment history; For patients with recurrent glioma, failure of standard therapy is required. 5. Performance status: Karnofsky performance status (KPS) score >=60, or Karf Fischer score index >=50. 6. Informed Consent: Patient or his/her legally authorized representative is willing to provide written informed consent. 7. Other: Cardiopulmonary function allows for related treatment operations.
Exclusion criteria
Exclusion criteria: 1. Tumor characteristics: presence of meningeal or spinal cord metastases; Tumors invade key areas of brain function (e.g., eloquence or motor areas); More than 3 glioma lesions 2. Treatment-related: refusal to use standard chemotherapy regimens (e.g., temozolomide); Is using or planning to use medications that may interact with the study drug 3. Imaging or surgical contraindications: there are contraindications to MRI, such as metal implants; deep brain tumors, where the introduction of an ultrasound probe increases the risk; Has a history of brain infection, 4. Other diseases or conditions: have other neurological diseases that may affect the results of the study; Pregnant or lactating women; Inability to cooperate with therapeutic procedures (e.g., claustrophobia); Presence of structural brain defects that affect tissue stiffness. 5. Allergies or contraindications: hypersensitivity to the study drug or related materials (such as aminosilane, iron oxide); Planned or currently being treated with the Optune®TTF System.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progress free of survival; | — |
Countries
China
Contacts
Public ContactXinjun Wang, Qiao Shan, Yuan Lyu, Junqi Li, Xianghui Wang
The Third Affiliated Hospital of Zhengzhou University
Outcome results
None listed